Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b

NCT01848639 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT01848639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01848639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Lead sponsor
University Hospital, Brest
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
November 30, 2022
Enrollment
823 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal failure on dialysis